Phase I lead-in to a 2x2x2 factorial trial of dose-dense temozolomide, memantine, mefloquine, and metformin as postradiation adjuvant therapy of glioblastoma (GBM).

被引：0
|
作者：
Penas-Prado, Marta
Groves, Morris D.
Mammoser, Aaron A.
Melguizo, Isaac
De Groot, John Frederick
Conrad, Charles A.
Tremont-Lukats, Ivo
Loghin, Monica Elena
Puduvalli, Vinay K.
Sulman, Erik P.
Hess, Kenneth R.
Aldape, Kenneth D.
Gilbert, Mark R.
Yung, W. K. Alfred
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Texas Oncol, Austin, TX USA
[3] Univ Michigan Hlth Syst, Ann Arbor, MI USA
[4] Baylor Charles A Sammons Canc Ctr, Neurooncol Associates, Dallas, TX USA
[5] Ohio Univ, James Canc Ctr, Columbus, OH USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2106
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma
    Maraka, Stefania
    Groves, Morris D.
    Mammoser, Aaron G.
    Melguizo-Gavilanes, Isaac
    Conrad, Charles A.
    Tremont-Lukats, Ivo W.
    Loghin, Monica E.
    Obrien, Barbara J.
    Puduvalli, Vinay K.
    Sulman, Erik P.
    Hess, Kenneth R.
    Aldape, Kenneth D.
    Gilbert, Mark R.
    de Groot, John F.
    Yung, W. K. Alfred
    Penas-Prado, Marta
    CANCER, 2019, 125 (03) : 424 - 433
  • [2] Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma (vol 125, pg 424, 2018)
    Maraka, S.
    Groves, M. D.
    Mammoser, A. G.
    CANCER, 2019, 125 (08) : 1387 - 1387
  • [3] Phase I factorial study of temozolomide plus memantine, mefloquine, and metformin as post-radiation adjuvant therapy for newly diagnosed glioblastoma.
    Maraka, Stefania
    Groves, Morris D.
    Mammoser, Aaron Gerald
    Melguizo-Gavilanes, Isaac
    Conrad, Charles A.
    Tremont-Lukats, Ivo
    Loghin, Monica Elena
    O'Brien, Barbara Jane
    Puduvalli, Vinay K.
    Sulman, Erik P.
    Hess, Kenneth R.
    Aldape, Kenneth D.
    Gilbert, Mark R.
    De Groot, John Frederick
    Yung, W. K. Alfred
    Penas-Prado, Marta
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma
    Gilbert, Mark R.
    Gonzalez, Javier
    Hunter, Kathy
    Hess, Kenneth
    Giglio, Pierre
    Chang, Eric
    Puduvalli, Vinay
    Groves, Morris D.
    Colman, Howard
    Conrad, Charles
    Levin, Victor
    Woo, Shaio
    Mahajan, Anita
    de Groot, John
    Yung, W. K. Alfred
    NEURO-ONCOLOGY, 2010, 12 (11) : 1167 - 1172
  • [5] RTOG 0525: A RANDOMIZED PHASE III TRIAL COMPARING STANDARD ADJUVANT TEMOZOLOMIDE (TMZ) WITH A DOSE-DENSE (DD) SCHEDULE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Gilbert, Mark R.
    Wang, Meihua
    Aldape, Ken D.
    Stupp, Roger
    Hegi, Monika
    Jaeckle, Kurt A.
    Armstrong, Terri S.
    Wefel, Jeffrey S.
    Won, Minhee
    Blumenthal, Deborah T.
    Mahajan, Anita
    Schultz, Christopher J.
    Erridge, Sara C.
    Brown, Paul D.
    Chakravarti, Arnab
    Curran, Walter J., Jr.
    Mehta, Minesh P.
    NEURO-ONCOLOGY, 2011, 13 : 51 - 51
  • [6] RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM).
    Gilbert, M. R.
    Wang, M.
    Aldape, K. D.
    Stupp, R.
    Hegi, M.
    Jaeckle, K. A.
    Armstrong, T. S.
    Wefel, J. S.
    Won, M.
    Blumenthal, D. T.
    Mahajan, A.
    Schultz, C. J.
    Erridge, S. C.
    Brown, P. D.
    Chakravarti, A.
    Curran, W. J.
    Mehta, M. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Fluorouracil and Dose-Dense Chemotherapy in Adjuvant Treatment of Patient with Early-Stage Breast Cancer: an Open-Label, 2 x 2 Factorial, Randomised Phase III Trial
    Colle, E.
    Besse, B.
    ONCOLOGIE, 2015, 17 (7-8) : 330 - 332
  • [8] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial
    Del Mastro, Lucia y
    De Placido, Sabino
    Bruzzi, Paolo
    De Laurentiis, Michele
    Boni, Corrado
    Cavazzini, Giovanna
    Durando, Antonio
    Turletti, Anna
    Nistico, Cecilia
    Valle, Enrichetta
    Garrone, Ornella
    Puglisi, Fabio
    Montemurro, Filippo
    Barni, Sandro
    Ardizzoni, Andrea
    Gamucci, Teresa
    Colantuoni, Giuseppe
    Giuliano, Mario
    Gravina, Adriano
    Papaldo, Paola
    Bighin, Claudia
    Bisagni, Giancarlo
    Forestieri, Valeria
    Cognetti, Francesco
    LANCET, 2015, 385 (9980): : 1863 - 1872
  • [9] A phase I study for a factorial design of dose-dense temozolomide (TMZ) alone and in combination with permutations of thalidomide (Thal), isotretinoin (CRA) and/or celecoxib (Cel) as post-chemoradiation adjuvant therapy for newly diagnosed glioblastoma (GBM)
    Gilbert, M. R.
    Gonzalez, J.
    Hunter, K.
    Hess, K.
    Chang, E.
    Puduvalli, V.
    Groves, M.
    Colman, H.
    Conrad, C.
    Levin, V.
    Woo, S.
    Mahajan, A.
    Hsu, S.
    de Groot, J.
    Yung, W. K. A.
    NEURO-ONCOLOGY, 2006, 8 (04) : 442 - 443
  • [10] RTOG 0525: Exploratory Subset Analysis from a Randomized Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-dense (dd) Schedule for Glioblastoma (GBM)
    Mehta, M. P.
    Wang, M.
    Aldape, K.
    Stupp, R.
    Jaeckle, K. A.
    Blumenthal, D.
    Brown, P.
    Erridge, S.
    Curran, W.
    Gilbert, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S128 - S129
12345